RLF — RELIEF THERAPEUTICS Holding SA Income Statement
0.000.00%
Last trade - 00:00
- CH₣29.47m
- CH₣21.16m
- CH₣6.03m
- 10
- 32
- 44
- 17
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 0 | 3.32 | 6.08 | 6.03 |
Cost of Revenue | |||||
Gross Profit | — | — | 2.57 | 4.83 | 4.3 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 12.1 | 5.7 | 37.6 | 58.1 | 117 |
Operating Profit | -12.1 | -5.7 | -34.3 | -52 | -111 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -12.2 | -6.26 | -35.5 | -54.3 | -112 |
Provision for Income Taxes | |||||
Net Income After Taxes | -7.46 | -7.83 | -34.7 | -50.8 | -98.2 |
Net Income Before Extraordinary Items | |||||
Net Income | -7.46 | -7.83 | -34.7 | -50.8 | -98.2 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -7.46 | -7.83 | -34.7 | -50.8 | -98.2 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.034 | -2.87 | -3.81 | -3.18 | -3.3 |
Dividends per Share |